How is CDKN1C implicated in cancer prognosis and therapy?
The expression levels of CDKN1C can serve as a prognostic marker in certain cancers. Low expression of CDKN1C is often associated with poor prognosis, higher tumor grade, and increased metastatic potential. Therapeutically, strategies to restore CDKN1C expression or function are being explored. These include epigenetic therapies to reverse gene silencing and small molecules to mimic CDKN1C activity. Understanding CDKN1C's dual role in cancer can aid in the development of targeted therapies that exploit its tumor suppressor functions while mitigating any oncogenic potential.
